Research and Development

Finding a treatment for Alzheimer’s disease has been one of the aims of big pharma for last few decades, but …

With ASCO occurring over the weekend, the headlines this week have been dominated by the news of breaking research that …

The worrying number of deaths associated with Nuplazid has eyes returning to the pipeline for Parkinson’s disease. Anjali Shukla, a …

Pfizer’s move to dump its neuroscience divisions caused serious ripples through the industry, with many wondering whether it heralded an …

Forty Seven, a spinout from Stanford University, has had a busy few days – first announcing that it had filed …

The FlyPharma Conference Europe wrapped up for another year on 6 June, returning with an expanded roster of speakers who …

Last week, Allergan announced that a strategic review of its operations had led to a decision to divest its women’s …

Mylan and Biocon have received FDA approval for their biosimilar to Amgen’s Neulasta (pegfilgrastim), setting the companies on track to …

In another major ASCO reveal, AstraZeneca and partner MSD lifted the curtain at the event on new data for its …

UK drug watchdog NICE has chosen to issue final guidance recommending the use of MSD’s Keytruda (pembrolizumab) on the NHS …

Just as it ramps up its cancer-fighting efforts, Eli Lilly has revealed that its Senior Vice President and President of …

The departure of high-level, big pharma executives to tiny biotechs is steadily becoming a constant stream; the latest is Bill …

The fact that Celgene is currently sailing through choppy waters is no secret to anyone within the industry, it’s facing …

Nektar Therapeutics has seen its share price devastated after revealing disappointing trial data for its candidate NKTR-214 in combination with …

Janssen took the opportunity at the American Society of Clinical Oncology (ASCO) annual event to present promising new Phase 2 …